ATG4B and chronic myelogenous leukemia, BCR-ABL1 positive: On the contrary, ATG4B is identified as a potential biomarker and therapeutic target of tyrosine kinase inhibitor-resistant chronic myeloid leukemia (CML) stem/progenitor cells [16].